Medicenna Therapeutics Corp. (MDNA.TO)

CAD 1.75

(-2.23%)

Operating Expenses Summary of Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp.'s latest annual operating expenses in 2023 was 19.66 Million CAD , up 20.61% from previous year.
Medicenna Therapeutics Corp.'s latest quarterly operating expenses in 2024 Q1 was 4.03 Million CAD , up 1.0% from previous quarter.
Medicenna Therapeutics Corp. reported a annual operating expenses of 16.3 Million CAD in annual operating expenses 2022, down -27.46% from previous year.
Medicenna Therapeutics Corp. reported a annual operating expenses of 22.47 Million CAD in annual operating expenses 2021, up 29.19% from previous year.
Medicenna Therapeutics Corp. reported a quarterly operating expenses of 18.66 Million CAD for 2023 FY, up 14.51% from previous quarter.
Medicenna Therapeutics Corp. reported a quarterly operating expenses of 4.77 Million CAD for 2023 Q3, down -12.18% from previous quarter.

Annual Operating Expenses Chart of Medicenna Therapeutics Corp. (2023 - 2013)

Historical Annual Operating Expenses of Medicenna Therapeutics Corp. (2023 - 2013)

Year	Operating Expenses	Operating Expenses Growth
2023	19.66 Million CAD	20.61%
2022	16.3 Million CAD	-27.46%
2021	22.47 Million CAD	29.19%
2020	17.39 Million CAD	110.98%
2019	8.24 Million CAD	74.41%
2018	4.72 Million CAD	-36.33%
2017	7.42 Million CAD	-3.55%
2016	7.69 Million CAD	541.69%
2015	1.19 Million CAD	43.96%
2014	833.31 Thousand CAD	8.55%
2013	767.69 Thousand CAD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	4.03 Million CAD	1.0%
2023 FY	18.66 Million CAD	14.51%
2023 Q3	4.77 Million CAD	-12.18%
2023 Q1	4.45 Million CAD	50.08%
2023 Q2	5.43 Million CAD	21.93%
2023 Q4	4 Million CAD	-16.23%
2022 Q2	4.08 Million CAD	-5.75%
2022 Q4	2.97 Million CAD	-39.63%
2022 Q3	4.92 Million CAD	20.58%
2022 Q1	4.33 Million CAD	38.47%
2022 FY	16.3 Million CAD	-27.46%
2021 Q4	3.12 Million CAD	-36.14%
2021 FY	22.47 Million CAD	29.19%
2021 Q1	6.21 Million CAD	8.86%
2021 Q2	8.23 Million CAD	32.45%
2021 Q3	4.89 Million CAD	-40.52%
2020 Q1	2.54 Million CAD	-4.49%
2020 FY	17.39 Million CAD	110.98%
2020 Q2	3.86 Million CAD	51.93%
2020 Q4	5.71 Million CAD	8.29%
2020 Q3	5.27 Million CAD	36.36%
2019 Q4	2.66 Million CAD	10.97%
2019 Q3	2.4 Million CAD	27.13%
2019 Q2	1.88 Million CAD	46.42%
2019 Q1	1.28 Million CAD	19.95%
2019 FY	8.24 Million CAD	74.41%
2018 FY	4.72 Million CAD	-36.33%
2018 Q4	1.07 Million CAD	-37.22%
2018 Q3	1.71 Million CAD	92.66%
2018 Q2	889.17 Thousand CAD	-15.28%
2018 Q1	1.04 Million CAD	-19.54%
2017 Q1	2.24 Million CAD	-48.69%
2017 Q4	1.3 Million CAD	-40.04%
2017 FY	7.42 Million CAD	-3.55%
2017 Q2	1.7 Million CAD	-24.13%
2017 Q3	2.17 Million CAD	27.85%
2016 Q1	10.65 Thousand CAD	20.73%
2016 FY	7.69 Million CAD	541.69%
2016 Q3	2.22 Million CAD	36145.11%
2016 Q4	4.37 Million CAD	96.84%
2016 Q2	6127.00 CAD	-42.51%
2015 Q2	157.11 Thousand CAD	964.29%
2015 Q4	8827.00 CAD	-98.44%
2015 Q3	566.08 Thousand CAD	260.31%
2015 FY	1.19 Million CAD	43.96%
2015 Q1	14.76 Thousand CAD	0.0%
2014 FY	833.31 Thousand CAD	8.55%
2013 FY	767.69 Thousand CAD	0.0%

Peer Operating Expenses Comparison of Medicenna Therapeutics Corp.

Name	Operating Expenses	Operating Expenses Difference
Appili Therapeutics Inc.	8.83 Million CAD	-122.509%
Eupraxia Pharmaceuticals Inc.	37.92 Million CAD	48.151%
Helix BioPharma Corp.	9.35 Million CAD	-110.142%
Microbix Biosystems Inc.	10.21 Million CAD	-92.439%
Satellos Bioscience Inc.	6.64 Million CAD	-195.862%
Oncolytics Biotech Inc.	33.79 Million CAD	41.81%
Sernova Corp.	41.13 Million CAD	52.194%